Combined activity of ketoconazole and 5-fluorocytosine on potentially pathogenic yeasts.
In vitro studies based on periodic viable count determinations indicated that the two antifungal drugs ketoconazole and 5-fluorocytosine generally were at least additive in their combined effect on various opportunistic yeast pathogens, including some resistant to 5-fluorocytosine.
D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects / Q000472:pathogenicity; D003596:Cytosine / Q000031:analogs & derivatives*; D004351:Drug Resistance; D004357:Drug Synergism; D005437:Flucytosine / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology*; D007654:Ketoconazole; D010879:Piperazines / Q000494:pharmacology*; D015003:Yeasts / Q000187:drug effects* / Q000472:pathogenicity
D000935:Antifungal Agents; D007093:Imidazoles; D010879:Piperazines; D003596:Cytosine; D005437:Flucytosine; D007654:Ketoconazole